

Claim Listing

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-14. Cancelled.

15. (Currently Amended) A therapeutic agent comprising:

a fused or chimeric polypeptide comprising

a first component comprising a polypeptide ~~capable of binding~~
that specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, wherein the polypeptide comprises the G3 subdomain of the laminin-5 $\alpha 3$ chain or a fragment, mutant, homolog, ortholog, analog, or allele thereof, and

a second component chemically bound to said first component, wherein said second component comprises an agent for use in the destruction or neutralization of a pathogen comprising at least one of $\alpha 6\beta 1$ integrin receptors and $\alpha 6\beta 4$ integrin receptors on the surface of the pathogen.

16. (Original) The therapeutic agent of claim 15, wherein the second component is a polypeptide.

17. (Withdrawn) The therapeutic agent of claim 15, wherein the second component is a non-protein agent.

18. (Original) The therapeutic agent of claim 15, wherein the second component is selected from the group consisting of IL-2, IL-3 IL-15, IL-12, IFN- γ , GM-CSF, CD40, CD40 ligand (CD40L), C3 Complement components, CD80, CD86, FAS, FAS ligand (FASL), superantigens, muramyl dipeptide (MDP), lipopolysaccharide (LPS), or mannose

19. (Original) The therapeutic composition of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:2.

20. (Original) The therapeutic composition of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:4.

21. (Original) The therapeutic composition of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:6.

22-42. Cancelled.

43. (New) The therapeutic composition of claim 15, wherein the first component comprises at least about 90% sequence identity with SEQ ID NO:2.

44. (New) The therapeutic composition of claim 15, wherein the first component comprises at least about 90% sequence identity with SEQ ID NO:4.

45. (New) The therapeutic composition of claim 15, wherein the first component comprises at least about 90% sequence identity with SEQ ID NO:6.

46. (New) The therapeutic composition of claim 15, wherein the first component consists of SEQ ID NO:6.

47. (New) The therapeutic composition of claim 15, wherein the first component comprises a segment consisting of SEQ ID NO:6.

48. (New) A fused or chimeric polypeptide comprising
a first component comprising a polypeptide, wherein the polypeptide comprises at least a segment of the G-domain of a laminin-5 $\alpha 3$ chain and the polypeptide specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor that specifically binds to a polypeptide comprising a segment consisting of SEQ ID NO:2, and

a second component chemically bound to said first component.

49. (New) The fused or chimeric polypeptide of claim 48, wherein the second component is a polypeptide.

50. (Withdrawn) The therapeutic agent of claim 48 wherein the second component is a non-protein agent.

51. (New) A fused or chimeric polypeptide comprising
a first component comprising a polypeptide, wherein the polypeptide comprises at least a segment of the G-domain of a laminin-5 $\alpha 3$ chain and the polypeptide specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor that specifically binds to a polypeptide comprising a segment consisting of SEQ ID NO:4, and

a second component chemically bound to said first component.

52. (New) The fused or chimeric polypeptide of claim 51, wherein the second component is a polypeptide.

53. (Withdrawn) The therapeutic agent of claim 51 wherein the second component is a non-protein agent.

54. (New) A fused or chimeric polypeptide comprising
a first component comprising a polypeptide, wherein the polypeptide comprises at least a segment of the G-domain of a laminin-5 $\alpha 3$ chain and the polypeptide specifically binds to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor that specifically binds to a polypeptide comprising a segment consisting of SEQ ID NO:6, and
a second component chemically bound to said first component.

55. (New) The fused or chimeric polypeptide of claim 54, wherein the second component is a polypeptide.

56. (Withdrawn) The therapeutic agent of claim 54 wherein the second component is a non-protein agent.